about
Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide componentNew candidate biomarkers in the female genital tract to evaluate microbicide toxicityA long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malariaEvaluation of the Activity of Lamivudine and Zidovudine against Ebola Virus.(+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium.Development of a new generation of 4-aminoquinoline antimalarial compounds using predictive pharmacokinetic and toxicology models.Preclinical Evaluations To Identify Optimal Linezolid Regimens for Tuberculosis Therapy.Orally bioavailable anti-HBV dinucleotide acyloxyalkyl prodrugsTransgenic mouse mutation assay systems can play an important role in regulatory mutagenicity testing in vivo for the detection of site-of-contact mutagens.Pharmacokinetics and dose-range finding toxicity of a novel anti-HIV active integrase inhibitor.Increased CCL2 expression and macrophage/monocyte migration during microbicide-induced vaginal irritation.Biodistribution, toxicology, and radiation dosimetry of 5-HT1A-receptor agonist positron emission tomography ligand [11C]CUMI-101.Evaluation of Antitrypanosomal Dihydroquinolines for Hepatotoxicity, Mutagenicity, and Methemoglobin Formation In VitroQuantitative proteomics for cardiac biomarker discovery using isoproterenol-treated nonhuman primates.Tenofovir disoproxil fumarate: toxicity, toxicokinetics, and toxicogenomics analysis after 13 weeks of oral administration in miceLead optimization of antimalarial propafenone analogues.Preclinical studies on the pharmacokinetics, safety, and toxicology of oxfendazole: toward first in human studies.Metabolism, pharmacokinetics, tissue distribution, and stability studies of the prodrug analog of an anti-hepatitis B virus dinucleoside phosphorothioate.Lead optimization of 3-carboxyl-4(1H)-quinolones to deliver orally bioavailable antimalarials.Evaluation of arylimidamides DB1955 and DB1960 as candidates against visceral leishmaniasis and Chagas' disease: in vivo efficacy, acute toxicity, pharmacokinetics, and toxicology studiesGene expression analysis reveals new possible mechanisms of vancomycin-induced nephrotoxicity and identifies gene markers candidates.Serum biomarkers reveal long-term cardiac injury in isoproterenol-treated African green monkeys.The role of hyperplasia in liver carcinogenesis.The role of cell proliferation in chemical carcinogenesis.Evaluation of Cardiac Toxicity Biomarkers in Rats from Different Laboratories.Professional toxicology societies: web based resources.Preclinical pharmacokinetic, toxicological and biomarker evaluation of SR16157, a novel dual-acting steroid sulfatase inhibitor and selective estrogen receptor modulator.Transgenic animal models for detection of in vivo mutations.Transgenic models for detection of mutations in tumors and normal tissues of rodents.Transgenic animal models for measuring mutations in vivo.A strategy for the application of transgenic rodent mutagenesis assays.Comparative studies on the genotoxic activity of mainstream smoke condensate from cigarettes which burn or only heat tobacco.Pharmacokinetics of the antimalarial drug, AQ-13, in rats and cynomolgus macaques.Genetic toxicology testing of the antimalarial drugs chloroquine and a new analog, AQ-13.Induction of unscheduled DNA synthesis in primary cultures of rat, mouse, hamster, monkey, and human hepatocytes.Skin irritation, basal epithelial cell proliferation, and carcinogenicity evaluations of a representative specialty acrylate and methacrylate.Spectrum of mutations in kidney, stomach, and liver from lacI transgenic mice recovered after treatment with tris(2,3-dibromopropyl)phosphate.Biodistribution, toxicity and radiation dosimetry studies of the serotonin transporter radioligand 4-[18F]-ADAM in rats and monkeys.Comparative mutagenicity testing of a drug candidate, U-48753E: mechanism of induction of gene mutations in mammalian cells and quantitation of potential hazard.WITHDRAWN. Neurological assessments after treatment with the antimalarial β-arteether in neonatal and adult rats.
P50
Q24650458-935C3C73-35C4-476A-B81D-5D9E5FA83C8AQ27334382-8EF8E8F6-3581-4720-8B54-48562E5D7665Q27644391-C9B8B626-8659-40A0-8008-057DF937D97AQ28554599-DD01D756-AD05-422C-AF94-78C4FC970726Q30610467-BF6B4C34-1F52-4A02-B549-BE390C011867Q30980255-4BBAF34A-F167-4052-BCD5-B71E6D5FDBAFQ33427278-72992045-2D50-4D79-A086-C27D592DCF7BQ33679312-63A24660-00ED-4FCF-92CE-FAFCB1D977D4Q33727327-FB9FE80B-8309-4E42-A100-7E91E498552FQ33911400-AB7FD716-784C-4FB3-ADE7-99CC91CB619EQ33943955-9D8D15F1-0471-42BF-9E59-15850543F5D1Q34214178-356D5C74-BC65-4562-A627-667178D8937CQ34498904-2D694F65-49BC-48B0-A8C4-716269CB285AQ34669434-A20A1425-4A99-4814-B5E8-534AC683E5FEQ35102322-B011F373-C1EB-4BE7-A2FB-F1B2794E2D36Q35535315-BD21913B-B23D-4423-902B-1C96C0C2C592Q35536978-64940D13-413D-4720-BE83-5A4BED294BD0Q35913071-B18F3E75-E587-40ED-B2E4-E55C2ED9058BQ35951799-EB575762-8489-4DD8-BA75-26D46395AD16Q36086468-CEA94F0A-C561-46BB-98CB-7CE7A7E69D96Q37089738-7FF20385-5835-4E8E-BEAD-F4149798945DQ37266056-8F55EA40-7CC6-42DF-AB78-3E1D0781138AQ37907841-834E69E9-F3AB-417C-9CB0-033DA6C2F9FEQ37941612-72EE5324-BA02-425D-8FB1-F6B3F08800E0Q39379692-588361A2-21BF-484D-8B6C-87D87560BA49Q39556944-CC1230F0-6829-47AE-86FA-9AF3DAD83106Q39844373-38DA1E8C-CB97-4256-AF7F-5863346A0F24Q40436922-5D36E880-B7AE-4734-9445-21CCDE537873Q40966983-D205258B-062C-4325-9153-D2F8525DE090Q41053143-0A5C0EE4-3FFF-4313-9D44-B5D24FDC415DQ41305000-DA851B6E-42AA-4686-8BBA-A9F8113B649DQ41748579-F558B1D7-CE1A-47C7-8CDA-0CB127C25343Q41913895-B0BF3B17-957F-434E-AC4C-CF8D0F7AF569Q41919272-F8F9A51B-E6A0-404F-A426-82654F8E05BFQ42209084-C9239347-BB00-403C-8BA9-18D41740BD2BQ42438938-5954863E-011F-4AC8-859C-54F1CE5DC50AQ42551646-BE63C18C-BD5F-453A-912A-1F7E13D8ADAAQ43263558-6E063911-9A03-4B16-B1C7-7F62C92AC937Q43679040-A5DFA890-D524-435C-8E49-705C7F428F56Q43893458-776FDD18-38E4-4546-B0EF-C715A6669C67
P50
description
American toxicologist and silent film score composer
@en
name
Jon C. Mirsalis
@en
Jon C. Mirsalis
@nl
type
label
Jon C. Mirsalis
@en
Jon C. Mirsalis
@nl
altLabel
Jon Carl Mirsalis
@en
Jon Mirsalis
@en
prefLabel
Jon C. Mirsalis
@en
Jon C. Mirsalis
@nl
P214
P244
P21
P213
0000 0000 4712 5178
P214
P244
no2008130067
P31
P345
P496
0000-0003-2391-8394
P569
1952-01-01T00:00:00Z